知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

9463 条记录 (耗时 0.042 秒)

    BLOOD CELL LYSIS REAGENT
    1.
    发明公开
    BLOOD CELL LYSIS REAGENT 审中-公开

    公开(公告)号：US20240360435A1

    公开(公告)日：2024-10-31

    申请号：US18771684

    申请日：2024-07-12

    申请人： Gen-Probe Incorporated

    发明人： Kui GAO ,  Jijumon CHELLISERRY ,  Jeffrey LINNEN

    IPC分类号： C12N15/10 ,  C12Q1/6806 ,  C12Q1/70

    CPC分类号： C12N15/1003 ,  C12Q1/6806 ,  C12Q1/70 ,  Y02A50/30

    摘要： Disclosed herein are lysis reagents for lysing red blood cells, thereby releasing an analyte, such as RNA from a host or pathogen, in a form suitable for analysis. The reagent includes at least a buffer, a detergent and one or both of a chloride containing salt and an anti-coagulant. The reagent serves to lyse blood cells, protect the released analyte from degradation in the lysate, and is compatible with subsequent steps for analysis of the analyte such as target capture, amplification, detection, or sequencing.

    MEANS AND METHODS FOR DIAGNOSING A VIRAL INFECTION OR A DISEASE ASSOCIATED THEREWITH
    3.
    发明公开
    MEANS AND METHODS FOR DIAGNOSING A VIRAL INFECTION OR A DISEASE ASSOCIATED THEREWITH 审中-公开

    公开(公告)号：US20240352542A1

    公开(公告)日：2024-10-24

    申请号：US18628273

    申请日：2024-04-05

    申请人： Bruker Biospin GmbH & Co. KG ,  Murdoch University

    发明人： Julien Wist ,  Samuele Sala ,  Philipp Nitschke ,  Jeremy K. Nicholson ,  Elaine Holmes ,  Christoph Trautwein ,  Claire Cannet

    IPC分类号： C12Q1/70 ,  C12Q1/6872 ,  C12Q1/6876

    CPC分类号： C12Q1/70 ,  C12Q1/6872 ,  C12Q1/6876

    摘要： The invention relates to the field of viral diagnosis. In particular, it is directed to a method for diagnosing a viral infection or a disease associated therewith in a subject comprising the steps of: (a) determining in a sample of said subject the amount of at least one biomarker selected from the group of 3′(,5′-di)deoxy-3′,4′-didehydro furanose derivatives of formula (I) with the exception of 3′-deoxy-3′,4′-didehydro-cytidine (ddhC); and (b) comparing the amount(s) of the at least one biomarkers determined in (a) with a reference, thereby diagnosing a viral infection.
    Further, the invention is directed to a method for diagnosing a viral infection or a disease associated therewith in a subject comprising the steps of: (A) determining in a sample of said subject the amount of 3′-deoxy-3′,4′-didehydro-cytidine (ddhC); and (B) comparing the amount of the ddhC determined in (A) with a reference, thereby diagnosing a viral infection; wherein the determination in (a) is done by NMR spectroscopy and the sample of the subject is a urine sample of said subject.
    The invention is also related to a diagnostic means for use in diagnosing a viral infection or a disease associated therewith, said diagnostic means comprising at least one biomarker selected from the group of 3′(,5′-di)deoxy-3′,4′-didehydro furanose derivatives of formula (I) with the exception of 3′-deoxy-3′,4′-didehydro-cytidine (ddhC), but also to a diagnostic means comprising 3′-deoxy-3′,4′-didehydro-cytidine (ddhC) for use in diagnosing a viral infection or a disease associated therewith, wherein the amount of the biomarker is determined done by NMR spectroscopy in a urine sample of a subject.
    Furthermore, the invention is directed to a device for diagnosing a viral infection or a disease associated therewith in a sample of a subject and to a kit for identifying a subject suffering from a viral infection or a disease associated therewith.

    METHODS FOR DETERMINATION OF TRANSPLANT REJECTION
    8.
    发明公开
    METHODS FOR DETERMINATION OF TRANSPLANT REJECTION 审中-公开

    公开(公告)号：US20240309472A1

    公开(公告)日：2024-09-19

    申请号：US18282390

    申请日：2022-03-16

    申请人： Natera, Inc.

    发明人： Phil GAUTHIER ,  Hossein TABRIZIANI ,  Paul VAN HUMMELEN ,  Jessica TANG

    IPC分类号： C12Q1/70 ,  C12Q1/6851 ,  C12Q1/6883

    CPC分类号： C12Q1/701 ,  C12Q1/6851 ,  C12Q1/6883 ,  C12Q2600/118 ,  C12Q2600/156

    摘要： The present disclosure provides methods for preparation and analysis of biological samples of transplant recipients for determination of transplant rejection, comprising: (a) measuring the amount of Torque teno virus (TTV) in a blood, plasma, serum, or urine sample of a transplant recipient; (b) measuring the amount of donor-derived cell-free DNA in a blood, plasma, serum, or urine sample of the transplant recipient; and (c) determining whether the amount of donor-derived cell-free DNA or a function thereof exceeds a cutoff threshold indicating transplant rejection and whether the transplant recipient has an increased or decreased amount of TTV indicating decreased or increased immune response, respectively.